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Abstract
Previous experiments have shown that chronic subcutaneous 
administration of nicotine dose-dependently inhibits the 
acquisition and retention of a spatial task in the Morris water 
maze and reduces cell genesis in the dentate gyrus (DG) of adult 
rats.1 In the present study, the effects of nicotine and buproprion, 
an atypical antidepressant used in smoking cessation, on dentate 
gyrus cell genesis and DNA fragmentation were investigated. 
The results show that nicotine, chronically infused for 21 days, 
suppressed cell genesis and enhanced DNA fragmentation 
in the DG, an effect not attenuated by co-administration of 
buproprion.
Introduction
The ability of the hippocampal formation, typically 
in its dentate gyrus (DG) area, to generate new neurons 
(neurogenesis) throughout the human lifespan2 may prove 
beneficial in the treatment of neurological diseases characterised 
by neuronal cell loss such as Alzheimer’s and Parkinson’s 
diseases. Increased neurogenesis can be produced by a variety 
of treatments including an enriched environment3, physical 
activity4 and antidepressant drugs.5,6 Neurogenesis has also 
been specifically implicated in learning tasks that involve the 
hippocampus.7,8
Clinical studies have revealed a strong correlation between 
the incidence of tobacco use and mood disorders.9 In animal 
models, nicotine, infused chronically using a procedure similar 
to the one reported here, was found to have antidepressant 
properties.10 Furthermore, nicotine dependence and withdrawal 
symptoms were ameliorated by buproprion11,12, an atypical 
antidepressant approved for smoking cessation13-15, probably 
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via a mechanism involving the inhibition of nicotinic 
acetylcholine receptors (nAChRs).16 In vitro studies revealed 
that buproprion exhibited some selectivity for neuronal nicotinic 
receptors that comprise a
3
β
2
, a
4
β
2
 and a
7
 subunits. Inhibition 
of radioactive nicotine binding to these receptor subtypes by 
buproprion suggested that the interaction was competitive and 
contributed to buproprion’s efficacy in counteracting nicotine 
dependence.17
It is widely reported that nicotine produces a protective effect 
against induced apoptosis18-21 in which one of the hallmarks is 
DNA fragmentation. Nevertheless, recent studies also suggest 
that nicotine enhances programmed cell death both in in vitro 
and in vivo systems22-24 also at concentration levels such as those 
reported in smokers.25,26 This study investigated the effects of 
constantly infused nicotine and buproprion on cell genesis (by 
determining BrDu incorporation) and DNA fragmentation in the 
DG. The nicotine dose chosen (4 mg/kg/day) results in blood 
nicotine concentrations (approximately 80 ng/ml) that would 
only be found in heavy smokers while the dose of buproprion 
(30 mg/kg/day) chosen was that reported to have antidepressant 
activity in the rat.27 A 21-day chronic drug administration 
schedule was consistent with the time course for the therapeutic 
action of antidepressant treatment.
Materials and methods
Subjects
Male Sprague-Dawley rats (Harlan Industries, UK), 
weighing 260-320g at the start of the experiment, were used. 
Rats were housed, two per cage, in a temperature-controlled 
(21°C) and humidity-controlled (50%±10%) environment on a 12 
hour light/dark cycle with lights on at 6.00 am. Food and water 
were provided ad libitum. All the experiments were conducted 
during the light phase of the cycle and were in accordance with 
the UK Home Office regulations and covered by a Home Office 
project licence.
Drug treatment
Rats were divided into four groups: a control group that 
received saline only (S-S), a nicotine-saline group that received 4 
mg/kg/day nicotine and saline (N-S), a buproprion-saline group 
that received 30 mg/kg/day buproprion and saline (B-S), and a 
nicotine-buproprion group that received 4 mg/kg/day nicotine 
and 30 mg/kg/day (N-B) (Table 1). All reagents were purchased 
24 Malta Medical Journal    Volume 18   Issue 03   October 2006
from commercially available sources unless otherwise indicated. 
Nicotine hydrogen tartrate (Sigma, UK) and buproprion (gift 
from GlaxoSmithKline, UK) were dissolved in 0.9% saline 
solution. The dose of nicotine hydrogen tartrate was calculated 
as that of the free base. Before filling the osmotic minipumps, 
drug solutions and vehicle were sterilised by filtration through 
a 0.2µm filter.
Osmotic minipumps (Alzet, ALZA Corporation, Palo Alto, 
CA, USA) were filled with drugs or vehicle as instructed by the 
manufacturer. They were implanted subcutaneously in the flank 
under inhalational anaesthesia (5% halothane for induction, 
3% for maintenance) through a small incision on the back at 
the level of the shoulders on day 1 of the experiment.  Two 
minipumps per rat, one on each side of the shoulder blade, were 
implanted (Table 1). 
Measurement of BrDu incorporation 
Cells formed from dividing progenitors were identified 
using bromodeoxyuridine (BrDu) (Sigma, UK) which integrates 
into DNA during the S-phase of DNA synthesis.28 BrDu was 
dissolved in 0.9% saline and administered (50 mg/kg) on days 
16-18 following implantation of minipumps. On day 21, rats 
were deeply anaesthetised with an overdose of pentobarbital 
sodium and perfused transcardially with 40 ml of saline followed 
by 140 ml of ice-cold paraformaldehyde (4% in 0.2 M sodium 
phosphate buffer, p.H. 7.4). Brains were removed and postfixed 
in paraformaldehyde solution for at least 24 h. Coronal sections 
(20 µm) were cut throughout the hippocampus using a cryostat. 
Every eighth section was thaw-mounted on slides.
Immunohistochemical techniques were used to identify the 
cells that had incorporated BrDu during cell division.  A neuronal 
nuclear protein marker (NeuN) was used to help visualise the 
neurones within the hippocampus and identify the borders of the 
DG.  To maximise antigen retrieval the following pretreatment 
steps were followed: DNA denaturation was performed by 
incubating the slides in 0.01 M citric acid (pH 6.0, 100°C, 10 
min) followed by membrane permeabilisation (0.01% trypsin 
in 0.1 M Tris/0.02 M CaCl
2
, 10 min) and acidification (2 M HCl, 
25 °C, 30 min). Non-specific binding of primary antibodies was 
blocked by incubating the slides in the blocking buffer PBST 
[phosphate buffered saline (PBS) containing 0.25% Triton X-
100 and 10% normal horse serum] for 1 h. The slides were then 
exposed to primary antibodies; mouse-anti-NeuN (Chemicon 
International, UK; 1:50) and rat-anti-BrDu (Harlan Sera-Lab, 
UK; 1:200) in PBST for 3 days at 4 °C. Sections were then 
washed in PBS for 10 min, blocked in PBST for 30 min and 
incubated with secondary antibodies [fluorescein isothiocyanate 
(FITC)-labelled anti-mouse IgG, Scottish Antibody Production 
Unit (SAPU); 1:50 and tetramethylrhodamine isothiocyanate 
(TRITC)-labelled anti-rat IgG, SAPU; 1:160] for 1 h at room 
temperature. The slides were then washed in PBS for 10 min and 
after adding a few drops of Vectorshield (Vector Laboratories, 
UK) coverslips were placed on the slides and sealed with clear 
nail varnish.
Slides were coded before counting to ensure objectivity. 
BrDu-labelled cells were visualised using a fluorescent 
microscope (Zeiss Axioskop II). Alternate sections were selected 
for analysis. Hence, eight hippocampal sections per rat were 
taken at intervals of 320 µm. All BrDu-labelled cells within the 
DG were counted and the number of BrDu-labelled cells for each 
subject was expressed as a mean per section.29
Analysis of DNA fragmentation
DNA fragmentation was detected by the non-isotopic 
TUNEL [terminal deoxynucleotidyl transferase (TdT)-mediated 
dUTP nick-end labelling] method using fluorescein-FragELTM 
DNA fragmentation detection kit (Oncogene, UK) as instructed 
by the manufacturer. In brief, the sections were gently immersed 
in Tris buffered saline (TBS) (20 mM Tris pH 7.6, 140 mM 
NaCl) for 15 min at room temperature. They were then covered 
with 100 µl of 20 µg/ml proteinase K for 10 min followed by 
washing in TBS. The sections were then incubated at room 
temperature for 10 – 30 min in TdT equilibration buffer and 60 
µl of TdT Labelling Reaction Mixture was then applied onto each 
section and covered with a parafilm coverslip. The slides were 
then incubated at 37ºC for 1 – 1.5 h in a humidified chamber 
followed by washing in TBS. The sections were mounted with 
a glass coverslip using the provided mounting media, sealed 
with nail polish and visualised using a standard fluorescein 
filter. Two hippocampal sections per rat at interval of 1.5 mm 
were taken and fluorescein-labelled cells in both the right 
and left DG of each section were counted and the number of 
fluorescein-labelled cells for each subject was expressed as a 
mean per section.
Data analysis
All data was analysed using the Statistical Package for 
Social Scientists (SPSS, Version 11.5) and the level of statistical 
significance was taken as p<0.05.  One-way analysis of variance 
(ANOVA) was used to determine group differences in BrDu and 
fluorescein-labelled cells (following data transformation for 
ranks) in the DG and post hoc using Tukey’s HSD test.
Results
Effect of nicotine and buproprion 
on BrDu incorporation in the DG
Chronic nicotine infusions reduced the number of BrDu-
labelled cells within the the DG by approximately four-fold 
compared to rats infused with saline only (Figure 1). Statistical 
analysis revealed a significant chronic nicotine treatment 
effect [F (1, 24) = 118.89, p<0.001]. No significant treatment 
effect on the number of BrDu-labelled cells was observed 
following chronic infusion with buproprion [F (1, 24) = 0.66, 
NS] or between the two treatment effects [F (1, 24) = 0.15, NS] 
denoting that nicotine reduced the number of BrDu-labelled 
cells irrespective of the presence of buproprion. Post hoc analysis 
confirmed that only the administration of nicotine reduced the 
number of cells produced compared to saline (p<0.001). 
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Effect of nicotine and buproprion 
on DNA fragmentation
Compared to the saline group, groups infused with nicotine 
increased the number of fluorescein-labelled cells in the DG 
(figure 2). Statistical analysis revealed a significant chronic 
nicotine treatment effect [F (1, 24) = 18.43, P <0.001] with 
no significant treatment effect on the number of fluoresceine-
labelled cells following chronic infusion with buproprion [F 
(1, 24) = 0.21, NS] or between the two treatment effects [F (1, 
24) = 0.27, NS] denoting that nicotine increased the number 
of fluorescein-labelled cells irrespective of the presence of 
buproprion. Post hoc analysis confirmed that only the groups in 
which nicotine was administered showed a significant increase 
in fluorescein-labelled cells and hence DNA fragmentation 
compared to saline (p<0.05).
Discussion
This study has shown that constant infusion of nicotine, 
irrespective of buproprion co-administration, produced a 
significant reduction in BrDu incorporation and enhanced DNA 
fragmentation within the DG of the hippocampal formation. 
Also, the administration of buproprion alone did not produce 
any significant cellular changes compared to saline-treated rats. 
The latter is in contrast with other classes of antidepressant 
drugs such as the tricyclic antidepressants, monoamine oxidase 
inhibitors and selective serotonin reuptake inhibitors which 
has been shown to up-regulate neurogenesis in the DG.30,31 
Although the mechanism of action of buproprion is not yet 
fully understood, the drug is believed to inhibit dopamine and 
noradrenaline uptake more potently than serotonin uptake.27,32 
Such buproprion-induced inhibition of dopamine and 
noradrenaline transporter function and the resultant increase in 
extracellular dopamine and noradrenaline levels may substitute 
for nicotine-evoked neurotransmitter release during smoking, 
although nicotine reinforcement primarily has been associated 
with increased dopamine release.33 
Together with nicotine replacement therapy, sustained 
release buproprion is efficacious as an aid in smoking cessation32, 
possibly by acting as a nAChR antagonist.17 However, this 
study showed that co-administration of buproprion did not 
influence nicotine-induced changes in cell genesis and DNA 
fragmentation with sustained administration denoting that the 
effects of nicotine probably do not depend upon stimulation 
of receptors antagonised by buproprion or by nicotine-evoked 
increase in dopamine or noradrenaline overflow. Also, the action 
of buproprion as a nAChR antagonist may be dose-dependent. 
In a self-administration paradigm in rats, Rauhut et al.34 
showed that treatment with buproprion decreased nicotine 
administration but only at the higher dose tested (78 mg/kg). 
In a similar experiment, Shoaib et al.12, using the same dose of 
buproprion as in our experiment, injected daily for 28 days, 
failed to reduce nicotine-self administration in rats. Any nAChR 
antagonism at a higher buproprion dose is therefore subject to 
further experimental analysis.
Stressful stimuli have been reported to inhibit cell genesis 
in the hippocampus.35 Nicotine, when administered at high 
doses, was found to have anxiogenic properties.36,37 Thus, 
it is possible that the effects of the higher dose of nicotine 
on BrDu incorporation in the hippocampus could reflect 
the stress evoked by nicotine administration. However, the 
studies that demonstrated an anxiogenic response to nicotine 
employed subcutaneous injections of the drug. In the present 
investigation, nicotine was given by slow infusion from a 
subcutaneous minipump that avoided the high peak in nicotine 
evoked by the administration of a subcutaneous bolus of the 
drug. Additionally, previous studies have shown that nicotine 
infused at the dose presented here does not elicit an anxiogenic 
response, at least when it is investigated using the elevated plus 
maze test of anxiety.38 These results imply that the chronic 
administration of nicotine by this route is not, in itself, stressful 
nor does it influence the response to an anxiogenic stimulus, 
such as the plus maze.
In this study, nicotine was also found to enhance DNA 
fragmentation, a hallmark of cell death via apoptosis or necrosis, 
in a dose that has previously been found to reduce spatial learning 
in the Morris water maze.1 The mechanism by which nicotine 
induces cell death is still unclear. Berger et al.25, and more 
recently Gimonet et al.24, argue that a
7
 nAChRs are important 
Table 1: Experimental protocol
Minipumps (M) containing nicotine, buproprion or the saline vehicle were inserted on day 1 of the experiment. On days 
16-18, the animals were injected with BrDu as described in the Materials and Methods section and transcardially perfused 
on day 21 followed by brain sectioning for immunohistochemical processing.
Drug treatment Day 1 Days 16-18 Day 21
Saline-Saline (S-S) M1: saline;  BrDu Transcardial perfusion
 M2: saline 
Saline-Nicotine (S-N) M1: saline;  BrDu Transcardial perfusion
 M2: nicotine (4 mg/kg/day) 
Saline-Buproprion (S-B) M1: saline;  BrDu Transcardial perfusion
 M2: buproprion (30 mg/kg/day) 
Nicotine-Buproprion (N-B) M1: nicotine (4 mg/kg/day);  BrDu Transcardial perfusion
 M2: buproprion (30 mg/kg/day)
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in mediating these effects, possibly by playing an important 
role as modulators of synaptic strength in the CNS39,40, and in 
processes involved in the pathophysiological changes observed 
in neurodegenerative diseases.41,42 The importance of these 
receptors during neural development indicates that they are 
crucial in the early stages of development and differentiation.43,44 
Also, nicotine appears to have contradictory effects on cell 
survival in different systems showing both protective45,46,47 and 
cytotoxic23,24,26 properties. The effect of nicotine on cell survival 
probably depends on a number of factors such as specific 
gene expression, cell cycle stage, developmental stage, levels 
of trophic factors, and calcium-buffering capabilities.48 The 
complex interaction of these effects could determine both the 
cytotoxic and protective effects of nicotine. 
In conclusion, this study has shown that the constant 
infusion of nicotine reduces cell genesis and enhance cell 
death in the DG. These effects were not attenuated by co-
administration of buproprion denoting the effects of nicotine 
probably do not depend upon stimulation of receptors 
antagonised by buproprion or by nicotine-evoked increase in 
dopamine or noradrenaline overflow.  These observations could 
have important implications on the understanding of the role of 
nicotinic cholinergic systems in neurodegenerative disorders. 
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